SQ-LIP-000038 · v1.1 (current) · machine-readable JSON →

Can screening tools or questionnaires help identify lipedema cases?

Knowledge freshness = share of the 15 indexed evidence sources from the last 5 years (newest 2026, oldest 2012) . Low freshness flags an ageing evidence base — not that the answer is wrong.

Evidence over time

consistent   conflicting   refining / contextual Each dot is a study, placed by year and coloured by whether the linked claim supports or contradicts the answer. As the surveillance loop runs, claim revisions and new evidence will extend this timeline.

Answer over time

Each node is a published version of the answer — open one to read the answer exactly as it stood then.

Consistent claims

• SCR-LIP-000188 consistent
  A simplified 9-item self-applied screening questionnaire (derived from the validated QuASiL) based on clinical diagnostic criteria (post-pubertal women, bilateral symmetric fat deposit below the hip sparing feet, negative Stemmer and Godet signs, pain on palpation, spontaneous bruising) achieved diagnostic discrimination of AUC=0.912 for an individual 7-question predictive model and AUC=0.8615 for a total-score model against expert clinical diagnosis in 109 women (59 with lipedema, 50 without), with the item 'feeling something wrong in the legs' being most discriminative (OR=4.328).
  Criação de questionário e modelo de rastreamento de lipedema — Amato et al. (2020)
• SCR-LIP-000009 consistent
  The Brazilian Portuguese lipedema symptoms questionnaire (QuASiL) was translated, culturally adapted and validated, showing high comprehension and symptom-intensity scores that correlate with limb volume by segmental bioimpedance.
  Tradução, adaptação cultural e validação do questionário de avaliação sintomática do lipedema (QuASiL) — Amato et al. (2020)
• SCR-LIP-000062 consistent
  A narrative review of 2020–2025 evidence concludes that systematic lipedema screening is necessary when studying pain–inflammation relationships in women with obesity, because unrecognized lipedema may cluster pain within peripheral fat phenotypes and bias comparisons between android and gynoid obesity groups.
  Dor crônica e biomarcadores inflamatórios em mulheres com obesidade: Impacto dos Fenótipos Adiposos e Lipedema — Silva et al. (2026)
• SCR-LIP-000065 consistent
  In a cohort of 1803 Spanish lipedema patients, 60.6% were diagnosed during reproductive years with a mean age of 42.9 years, and the study presents a novel clinical assessment approach including multiple comorbidity markers (e.g., suspected high intestinal permeability in 99%, bilateral trochanteric pain in 97.4%, ligamentous hyperlaxity in 95.8%) that may help physicians better identify and understand the condition.
  Clinical Signs at Diagnosis and Comorbidities in a Large Cohort of Patients with Lipedema in Spain — Simarro Blasco et al. (2025)
• SCR-LIP-000364 consistent
  In a cross-sectional survey of 969 Spanish lipedema patients, diagnoses used the Schingale type I-IV classification (type III 41.7%, type IV 36.8%, type II 17.8%, type I 3.7%) and a modified Wolf/Herbst 13-criteria symptom scale; the authors validated a threshold of ≥6 of 13 symptoms (Mann-Whitney p=0.666 showing no distributional difference between diagnosed and undiagnosed groups), and diagnosis often required multiple consultations (51.2% needed ≥3 specialists).
  The Advanced Care Study: Current Status of Lipedema in Spain, A Descriptive Cross-Sectional Study — Carballeira Braña & Poveda Castillo (2023)
• SCR-LIP-000068 consistent
  Dutch lipedema guidelines conclude that lipedema is frequently misdiagnosed or wrongly classified as an aesthetic problem, and recommend a minimum data set of repeated clinical measurements (waist circumference, limb circumferences, BMI, and psychosocial distress scoring) to ensure early detection.
  First Dutch guidelines on lipedema using the international classification of functioning, disability and health — Halk & Damstra (2017)
• SCR-LIP-000275 consistent
  Using a previously validated online screening questionnaire (cutoff ≥12 points, AUC 0.8615, specificity 0.88, sensitivity 0.46, PPV 0.767), a population-representative study estimated lipedema prevalence at 12.3% among Brazilian women aged 18-69, corresponding to roughly 8.8 million women with suggestive symptoms.
  Prevalência e fatores de risco para lipedema no Brasil — Amato et al. (2022)
• SCR-LIP-000358 consistent
  The authors propose a clinical-ultrasonographic diagnostic algorithm for abdominal lipedema using maximum criteria (symmetric abdominal fat deposition + ultrasonographic evidence + inelastic skin), major criteria (pain on palpation + non-response to diet/exercise), and minor criteria (easy bruising + heaviness), correlating abdominal involvement with lipedema stage (31% in stage II, 70% in stage III).
  Abdominal Lipedema: Clinical Diagnosis and Management Through a Proposed Diagnostic Algorithm — Bruno & Cilluffo (2025)
• SCR-LIP-000277 consistent
  In non-obese lipedema patients, standardized QST (DFNS protocol) revealed selective alterations in only 2 of 13 parameters at the affected lateral thigh—elevated pressure pain (PPT, AUC 0.9075) and reduced vibration detection (VDT, AUC 0.8638)—and a combined PPT+VDT z-score score was proposed as a rapid diagnostic test for lipedema.
  Non-obese lipedema patients show a distinctly altered Quantitative Sensory Testing profile with high diagnostic potential — Dinnendahl et al. (2023)
• SCR-LIP-000199 consistent
  In a DXA body composition study, the leg fat mass/total fat mass index distinguished lipedema patients from healthy controls with AUC=0.90 (sensitivity 0.95, specificity 0.73 at cutoff 0.383) across all BMI strata, with elevated leg fat proportion (0.451 vs 0.354) and inverted trunk/legs ratio (0.960 vs 1.502), while appendicular lean mass and total bone density did not differ.
  Body Composition Assessment by Dual-Energy X-Ray Absorptiometry: A Useful Tool for the Diagnosis of Lipedema — Buso et al. (2022)
• SCR-LIP-000285 consistent
  A systematic review reported that lipedema is poorly recognized clinically—only 46.2% of 251 Vascular Society of Great Britain and Ireland consultants recognized it (Tiwari 2006)—and that it was absent from MeSH/EMBASE and ICD-WHO as of 2012, while non-contrast CT showed 95% sensitivity and 100% specificity and the spared foot dorsum (negative Stemmer sign) helps distinguish lipedema from lymphedema.
  Lipedema: an overview of its clinical manifestations, diagnosis and treatment of the disproportional fatty deposition syndrome – systematic review — Forner‐Cordero et al. (2012)
• SCR-LIP-000191 consistent
  Bioimpedance spectroscopy of regional tissue fluid distinguished lipedema from Dercum's disease (lower leg/arm R0 ratio in lipedema, p<0.001) and detected stage 1 lipedema versus matched controls (leg/arm ratio R0 p=0.01, R1 p=0.007), with leg extracellular water increasing across lipedema stages (p=0.03), proposing BIS as an objective adjunct biomarker for diagnosis and staging.
  Lipedema and Dercum's Disease: A New Application of Bioimpedance — Crescenzi et al. (2019)
• SCR-LIP-000287 consistent
  In a case-control study, carriers of the IL-6 rs1800795 G allele had a 5.92-fold higher risk of lipedema (OR=5.92, 95%CI 1.983–17.711, p<0.001), and DXA-derived body composition indices (reduced WHR 0.73 vs 0.79, higher lower-limb FM% 48.90% vs 42.55%) combined with genetic analysis were proposed as tools for differential diagnosis between lipedema, normal-weight obesity, and obesity.
  The role of IL-6 gene polymorphisms in the risk of lipedema — Di Renzo L et al. (2020)
• SCR-LIP-000288 consistent
  In a prospective cohort of 138 lipedema and 111 lymphedema patients, a CART algorithm using only three clinical variables (bruising, body disproportion, and non-swollen/spared feet) classified lipedema versus lymphedema with 100% accuracy, and the median time from symptom onset to diagnosis was markedly longer in lipedema (25.5 years vs 12.1 years for lymphedema, p<0.0001).
  Building evidence for diagnosis of lipedema: using a classification and regression tree (CART) algorithm to differentiate lipedema from lymphedema patients — FORNER-CORDERO et al. (2025)

Conflicting claims

• None indexed yet.

Refining / contextual

• SCR-LIP-000279 context
  This editorial commenting on Crescenzi et al. (2023) emphasizes the lack of reliable lipedema biomarkers and highlights noncontrast 3T MR lymphangiography—which reveals subcutaneous adipose tissue edema and increased lymphatic load—as a promising imaging biomarker that could aid differential diagnosis between lipedema and obesity, while noting small sample sizes limit current evidence.
  Editorial for “Subcutaneous Adipose Tissue Edema in Lipedema Revealed by Noninvasive 3T Magnetic Resonance Lymphangiography” — Wang (2023)

Major uncertainty

Validation is fragmented and mostly low-grade: questionnaires and algorithms are validated against expert clinical diagnosis (no objective gold standard), in single regions/centers, with limited external replication; reported accuracies (including the 100% CART and 95–100% CT figures) lack independent validation and prospective confirmation. Sensitivity of the leading questionnaire is low (0.46), risking missed cases, and no head-to-head comparison establishes which tool is best for population vs clinical screening.

Version history

• SQ-LIP-000038 · v1.1 — 2026-06-02 — Answer recompiled after human curation of the claim set. · view this version
• SQ-LIP-000038 · v1.0 — 2026-06-02 — Decomposed from umbrella SQ-LIP-000004 (R-Q-7). · snapshot not archived

Key references

DOI:10.1590/1677-5449.200114 · DOI:10.1590/1677-5449.200049 · DOI:10.36557/2674-8169.2026v8n2p869-884 · DOI:10.3390/biomedicines13123049 · DOI:10.3390/ijerph20176647 · DOI:10.1177/0268355516639421 · DOI:10.1590/1677-5449.202101981 · DOI:10.1007/s00266-025-05192-1 · DOI:10.1101/2023.04.25.23289086 · DOI:10.1159/000527138 · DOI:10.1002/jmri.28400 · DOI:10.1111/j.1758-8111.2012.00045.x · DOI:10.1089/lrb.2019.0011 · DOI:10.26355/eurrev_202003_20690 · DOI:10.23736/s0392-9590.25.05207-1

← All questions